Is Ginkgo Bioworks Holdings, Inc. (DNA) a Buy, Sell, or Hold?
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$9.04 USD
-$0.01 (-0.11%)
- Volume
- 703.17K
- Average Volume
- 1.29M
- Market Capitalization
- $590.53M
- P/E Ratio
- -1.68
- Dividend Yield
- 0.00%
- Price Target
- $7.50
- Year High
- $17.58
- Year Low
- $5.37
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.15
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Jason Kelly |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DNA |
| CUSIP | 37611X209 |
| CIK | 0001830214 |
| Web | https://www.ginkgobioworks.com |
| Phone | 877 422 5362 |
| Currency | USD |
| Employees | 485 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.93 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.15 |
| Quick Ratio | 5.15 |
| Cash Ratio | 1.81 |
Sales & Book Value
| Annual Sales | $170.16M |
| Price / Sales | 4.18 |
| Cash Flow | -3.08 |
| Price / Cash Flow | -3.22 |
| Price / Book | 1.22 |
Price Target and Rating
| Average Stock Price Forecast | $7.50 |
| High Stock Price Forecast | $12.00 |
| Low Stock Price Forecast | $4.35 |
| Forecast Upside/Downside | 20.53% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.64 |
| Trailing P/E Ratio | -1.68 |
| PEG Ratio | -0.04 |
| P/E Growth | -0.04 |
| Net Income | $-312.76M |
| Net Margin | -215.41% |
| Pretax Margin | -211.50% |
| Return on Equity | -57.31% |
| Return on Assets | -29.46% |
Financials Score
| AltmanZ Score | -8.28 |
| Piotroski Score | 2.00 |
| Working Capital | 330.36M |
| Total Assets | 1.03B |
| Ebit | -300.15M |
| Market Cap | 591.19M |
| Total Liabilities | 589.92M |
Poll Results
About Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, fou ... nded in 2008, is headquartered in Boston, Massachusetts.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
2026-07-08 05:45:00
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
2026-07-07 08:30:00
SAN FRANCISCO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Applied Biosystems™ RapidINTEL™ Plus Cartridge has received approval from the Federal Bureau of Investigation (FBI) National DNA Index System (NDIS) for use with qualifying forensic crime scene samples. The law enforcement milestone makes Thermo Fisher's Rapid DNA workflow on the RapidHIT ID™ System the first eligible to generate DNA profiles that can be searched against the n.
2026-07-02 08:00:00
Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation (“EG BioMed US”), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company's transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think
2026-06-28 11:30:00
A new biosecurity theme is emerging, and Palantir is leveraging it as an opportunity. Here's why that divide could matter for investors.
FTAI Aviation: Innovation Is Their DNA
2026-06-07 08:52:38
FTAI Aviation is innovatively leveraging jet engine cores to address the urgent power needs of data centers amid an energy bottleneck. FTAI's new power segment, repurposing CFM56 engines, could add 30% to company value by 2027, with significant upside if unit deliveries meet targets. The stock is rated Buy, with a $393 price target (57% upside) based on 25 power units sold in 2027; risk increases as FTAI enters the energy sector.
2026-06-01 08:58:00
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
2026-05-29 08:15:00
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Tempus xT CDx is a 648.
2026-05-26 12:33:00
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.
Frequently Asked Questions
-
What is the current Ginkgo Bioworks Holdings, Inc. (DNA) stock price?
-
Ginkgo Bioworks Holdings, Inc.(NYSE:DNA) stock price is $9.04 in the last trading session. During the trading session, DNA stock reached the peak price of $17.58 while $5.37 was the lowest point it dropped to. The percentage change in DNA stock occurred in the recent session was --0.11% while the dollar amount for the price change in DNA stock was -$-0.01.
-
DNA's industry and sector of operation?
-
The NYSE listed DNA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DNA?
-
Steven Coen | Chief Financial Officer
Reshma Shetty | Co-Founder, President & Director
Jennifer Wipf | Co-Chief Operating Officer
Karen Tepichin | General Counsel & Secretary
Brian O'sullivan | Head of Commercial -
How many employees does DNA have?
-
Number of DNA employees currently stands at 485. DNA operates from 27 Drydock Avenue, Boston, MA 02210, US.
-
Link for DNA official website?
-
Official Website of DNA is: https://www.ginkgobioworks.com
-
How do I contact DNA?
-
DNA could be contacted at phone #877 422 5362 and can also be accessed through its website. DNA operates from 27 Drydock Avenue, Boston, MA 02210, US.
-
How many shares of DNA are traded daily?
-
The average number of DNA shares traded daily for last 3 months was 1.29M.
-
What is the market cap of DNA currently?
-
The market value of DNA currently stands at $590.53M with its latest stock price at $9.04